Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 4, 2010, Pages 1436-1439

  Lloyd, John ^a   Finlay, Heather J ^a   Vacarro, Wayne ^a   Hyunh, Tram ^a   Kover, Alexander ^a   Bhandaru, Rao ^a   Yan, Lin ^a   Atwal, Karnail ^a   Conder, Mary Lee ^a   Jenkins West, Tonya ^a   Shi, Hong ^a   Huang, Christine ^a   Li, Danshi ^a   Sun, Huabin ^a   Levesque, Paul ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Atrial fibrillation; IKur; Kv1.5; Potassium channel blocker

Indexed keywords

2 (4 FLUOROPHENYL)PYRROLIDINE AMIDE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; PYRAZOLODIHYDROPYRIMIDINE DERIVATIVE; PYRROLIDINE AMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIGINELLI REACTION; CONTROLLED STUDY; DEPROTECTION REACTION; DIASTEREOISOMER; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL DOG; HEART MUSCLE REFRACTORY PERIOD; IC 50; MOUSE; NONHUMAN; POTASSIUM CURRENT; RAT; STEREOCHEMISTRY;

AMIDES; ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; KV1.5 POTASSIUM CHANNEL; MOLECULAR STRUCTURE; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; PYRROLIDINES; RABBITS; RATS;

ORYCTOLAGUS CUNICULUS;

EID: 75449116397     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.085     Document Type: Article

References (15)

1. Wattigney W.A., Mensah G.A., and Croft J.B. Circulation 108 (2003) 711
2. Wolf P.A., Mitchell J.B., Baker C.S., et al. Arch Int. Med. 158 (1998) 229
3. Nattel S., Khairy P., Roy D., Thibault B., Guerra P., Talajic M., and Dubuc M. Drugs 62 (2002) 2377
4. Roden D.M. Br. J. Pharmacol. 154 (2008) 1502
5. Amos G.J., Wettwer E., Li Q., Himmel H.M., and Ravens U. Circulation 90 (1994) I-581a
6. Li G.R., Feng J., Yue L., Carrier M., and Nattel S. Circ. Res. 78 (1996) 689
7. Vacarro W., Huynh T., Lloyd J., Atwal K.S., Finlay H.J., Levesque P.C., Conder M.L., Jenkins-West T., Shi H., and Sun L. Bioorg. Med. Chem. Lett. I18 (2008) 6381
8. Sorgi K.L., Maryanoff C.A., McComsey D.F., and Maryanoff B.E. Org. Synth. 75 (1998) 215
9. Garvey D.S., Wasicak J.T., Elliott R.L., Lebold S., Hettinger A.-M., Carrera G.M., Lin N.-H., He Y., and Holladay M.W. J. Med. Chem. 37 (1994) 4455
10. Snyders D.J., Tamkun M.M., and Bennet P.B. J. Gen. Physiol. 101 (1993) 513
11. Zhou Z., Vorperian V., Gong Q., Zhang S., and January C.T. J. Cardiovas. Electrophys. 10 (1999) 836
12. Abriel H., Wehrens X.H.T., Benhorin J., Kerem B., and Kass R.S. Circulation 102 (2000) 921
13. Fearon I.M., Ball S.G., and Peers C. Br. J. Pharmacol. 129 (2000) 547
14. dss) were calculated after intra-arterial administration. The absolute oral bioavailability (F, expressed as %) was estimated by taking the ratio of dose-normalized AUC value after an oral dose to that after an intra-arterial dose.
15. Sun H., Lloyd J., Shi H., Li D., and Levesque P. Heart Rhythm. 5 (2008) S213